Adocia Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
80
- Stock Symbol
-
ADOC
- Share Price
-
$3.88
- (As of Thursday Closing)
Adocia General Information
Description
Adocia is a clinical-stage biotechnology company focused on developing treatments for diabetes, obesity, and related metabolic diseases. The company uses its proprietary BioChaperone, AdoShell, AdOral and AdoXLong technology platforms to develop improved formulations of therapeutic proteins and peptides, oral and long-acting metabolic treatments, and immunoprotective cell-therapy solutions. Its pipeline includes BioChaperone Lispro, BioChaperone GLP-1 Amylin, AdoXLong Sema, AdOral Sema, AdoShell Islets and M1Pram.
Contact Information
Website
www.adocia.comCorporate Office
- 115 Avenue Lacassagne
- 69003 Lyon
- France
Corporate Office
- 115 Avenue Lacassagne
- 69003 Lyon
- France
Adocia Timeline
Adocia Stock Performance
As of 19-Nov-2026, Adocia’s stock price is $3.88. Its current market cap is $87.7M with 22.6M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.88 | $3.88 | $2.25 - $9.92 | $87.7M | 22.6M | 333K | -$0.89 |
Adocia Financials Summary
As of 30-Jun-2026, Adocia has a trailing 12-month revenue of $568K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 83,938 | 158,093 | 99,691 | 197,717 |
| Revenue | 568 | 1,664 | 10,086 | 2,326 |
| EBITDA | (16,846) | (17,354) | (7,505) | (21,031) |
| Net Income | (18,543) | (18,715) | (10,086) | (22,899) |
| Total Assets | 24,483 | 33,423 | 28,115 | 27,586 |
| Total Debt | 9,180 | 10,456 | 8,918 | 12,459 |
Adocia Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Adocia Comparisons
Industry
Financing
Details
Adocia Competitors (66)
One of Adocia’s 66 competitors is Roivant Sciences, a Formerly PE-Backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Roivant Sciences | Formerly PE-Backed | New York, NY | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Denovo Biopharma | Venture Capital-Backed | Hangzhou, China | ||||
| Incyte | Formerly VC-backed | Wilmington, DE |
Adocia Patents
Adocia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12544349-B1 | Compositions comprising pemvidutide and an acylated amino acid | Active | 30-Dec-2024 | ||
| EP-4721760-A1 | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | Pending | 07-Oct-2024 | ||
| EP-4721761-A1 | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | Pending | 07-Oct-2024 | ||
| EP-4684802-A1 | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | Pending | 23-Jul-2024 | ||
| EP-4684801-A1 | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | Pending | 23-Jul-2024 | A61K9/0019 |
Adocia Signals
Adocia Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Adocia ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Adocia FAQs
-
When was Adocia founded?
Adocia was founded in 2005.
-
Where is Adocia headquartered?
Adocia is headquartered in Lyon, France.
-
What is the size of Adocia?
Adocia has 80 total employees.
-
What industry is Adocia in?
Adocia’s primary industry is Biotechnology.
-
Is Adocia a private or public company?
Adocia is a Public company.
-
What is Adocia’s stock symbol?
The ticker symbol for Adocia is ADOC.
-
What is the current stock price of Adocia?
As of 19-Nov-2026 the stock price of Adocia is $3.88.
-
What is the current market cap of Adocia?
The current market capitalization of Adocia is $87.7M.
-
What is Adocia’s current revenue?
The trailing twelve month revenue for Adocia is $568K.
-
Who are Adocia’s competitors?
Roivant Sciences, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Denovo Biopharma, and Incyte are some of the 66 competitors of Adocia.
-
What is Adocia’s annual earnings per share (EPS)?
Adocia’s EPS for 12 months was -$0.89.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process